Tenofovir alafenamide hemifumarate

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Warnung

• Gefahrenhinweise

  H302：Gesundheitsschädlich bei Verschlucken.

  H315：Verursacht Hautreizungen.

  H319：Verursacht schwere Augenreizung.

  H335：Kann die Atemwege reizen.

• Sicherheit

  P261：Einatmen von Staub vermeiden.

  P305+P351+P338：BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

Tenofovir alafenamide hemifumarate Chemische Eigenschaften,Einsatz,Produktion Methoden

• Beschreibung

  Tenofovir alafenamide hemifumarate is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor.

• Chemische Eigenschaften

  White to almost White crystal or crystalline powder.

• Originator

  Gilead Sciences

• Verwenden

  Tenofovir alafenamide hemifumarate is a newer, more effective prodrug used in combination with FTC that has recently been approved for the prevention of HIV transmission through the rectum. It is used to treat chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.

• Definition

  ChEBI: A fumarate salt prepared from tenofovir alafenamide by reaction of one molecule of fumaric acid for every two molecules of tenofovir alafenamide. A prodrug for tenofovir, it is used in combination therapy for the treatment of HIV-1 infection.

• Clinical Use

  Tenofovir alafenamide hemifumarate is useful in the treatment and/or prophylaxis of one or more viral infections in man or animals, including infections caused by DNA viruses. RNA viruses, herpesviruses (e.g., CMV, HSV 1, HSV 2, VZV), retroviruses, hepadnaviruses (e.g., HBV), papillomavirus, hantavirus, adenoviruses and HIV. Like tenofovir disoproxil, tenofovir alafenamide is another prodrug form of tenofovir, and can be used in the treatment and/or prophylaxis of the same conditions.

• Nebenwirkungen

  Check with your doctor immediately if any of the following side effects occur:
  Abdominal or stomach discomfort,bloody urine,dark urine,decreased appetite,decreased frequency or amount of urine,troubled breathing,cough,headache,back pain.

• Synthese

  Under a nitrogen atmosphere, 200 g of isopropanol, 9 g of fumaric acid, and 50 g of TAF-3 were sequentially added to a 2 L reaction flask. Turn on the stirring, control the temperature at 40 ~ 50 °C, stir and dissolve, filter while hot, collect the mother liquor. Transfer the mother liquor to a 2L reaction bottle, start stirring, control the temperature at 40 ~ 50 °C, stir and dissolve, slowly reduce the temperature to 0 ~ 5 ° C, cooling time 2 ~ 3 hours, heat stirring for 10 hours. Filtration, drying at 60-65 ° C for 12 to 16 hours, to obtain 37.5 g of Tenofovir Alafenamide Fumarate finished product, white powder, yield 75.0%.
  

• Arzneimittelwechselwirkung

  Some products that may interact with this drug are: adefovir, orlistat, other drugs that may harm the kidneys (including aminoglycosides such as amikacin/gentamicin).

• Advantages

  One major advantage of the hemifumarate form of tenofovir alafenamide over the monofumarate form is its exceptional capability to purge GS-7339 (i.e., 9-[(R)-2-[[(R)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine, which is the major diastereomeric impurity in the active pharmaceutical ingredient. Thus, the hemifumarate form of tenofovir alafenamide can be more readily and easily separated from impurities than the monofumarate form. Other major advantages of tenofovir alafenamide hemifumarate over the monofumarate form include improved thermodynamic and chemical stability (including long-term storage stability), superior process reproducibility, superior drug product content uniformity, and a higher melting point.

Tenofovir alafenamide hemifumarate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(310)Suppliers